{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:47:32Z","timestamp":1789958852707,"version":"4.0.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01020-y","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T06:02:01Z","timestamp":1709704921000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical outcomes of patients with lymphoid blastic phase of chronic myeloid leukemia treated with CAR T-cell therapy"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1301-2666","authenticated-orcid":false,"given":"Yujie","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biqi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiannan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9301-641X","authenticated-orcid":false,"given":"Tianhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6312-3863","authenticated-orcid":false,"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4643-2098","authenticated-orcid":false,"given":"Yang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"1020_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"1020_CR2","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"1020_CR3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","volume":"120","author":"R Hehlmann","year":"2012","unstructured":"Hehlmann R. How I treat CML blast crisis. Blood. 2012;120:737\u201347.","journal-title":"Blood"},{"key":"1020_CR4","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim WA, June CH. The Principles of Engineering Immune Cells to Treat Cancer. Cell. 2017;168:724\u201340.","journal-title":"Cell"},{"key":"1020_CR5","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1182\/bloodadvances.2022009072","volume":"7","author":"L Chen","year":"2023","unstructured":"Chen L, Gong W-J, Li M-H, Zhou H-X, Xu M-Z, Qian C-S, et al. Anti-CD19 CAR T-Cell consolidation therapy combined with CD19+ feeding T cells and TKI for Ph+ acute lymphoblastic leukemia. Blood Adv. 2023;7:4913\u201325.","journal-title":"Blood Adv"},{"key":"1020_CR6","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.2147\/OTT.S235882","volume":"13","author":"J Hua","year":"2020","unstructured":"Hua J, Qian W, Wu X, Zhou L, Yu L, Chen S, et al. Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature. Onco Targets Ther. 2020;13:2311\u20137.","journal-title":"Onco Targets Ther"},{"key":"1020_CR7","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/leu.2011.355","volume":"26","author":"FJ Giles","year":"2012","unstructured":"Giles FJ, Kantarjian HM, le Coutre PD, Baccarani M, Mahon FX, Blakesley RE, et al. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia. 2012;26:959\u201362.","journal-title":"Leukemia"},{"key":"1020_CR8","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1007\/s12015-020-10008-7","volume":"16","author":"F Liu","year":"2020","unstructured":"Liu F, Sha S, Ma G, Su Y, Xiong Y, He G, et al. Treatment of CML-transformed B Cell Acute Lymphoblastic Leukemia (B-ALL) in Adults with Anti-CD19 Chimeric Antigen Receptor T Cell (CAR T) Therapy. Stem Cell Rev Rep. 2020;16:1356\u20138.","journal-title":"Stem Cell Rev Rep."},{"key":"1020_CR9","doi-asserted-by":"publisher","first-page":"10989","DOI":"10.2147\/OTT.S232102","volume":"12","author":"L Zhou","year":"2019","unstructured":"Zhou L, Shi H, Shi W, Yang L, Zhang Y, Xu M, et al. Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy. Onco Targets Ther. 2019;12:10989\u201395.","journal-title":"Onco Targets Ther"},{"key":"1020_CR10","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"S Soverini","year":"2011","unstructured":"Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118:1208\u201315.","journal-title":"Blood"},{"key":"1020_CR11","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O\u2019Hare","year":"2007","unstructured":"O\u2019Hare T, Eide CA, Deininger MWN. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007;110:2242\u20139.","journal-title":"Blood"},{"key":"1020_CR12","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.3109\/10428194.2011.578310","volume":"52","author":"RM Bengi\u00f3","year":"2011","unstructured":"Bengi\u00f3 RM, Riva ME, Moiraghi B, Lanari E, Milone J, Ventriglia V, et al. Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study. Leuk Lymphoma. 2011;52:1720\u20136.","journal-title":"Leuk Lymphoma"},{"key":"1020_CR13","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1182\/blood.2019002936","volume":"135","author":"J Gauthier","year":"2020","unstructured":"Gauthier J, Hirayama AV, Purushe J, Hay KA, Lymp J, Li DH, et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020;135:1650\u201360.","journal-title":"Blood"},{"key":"1020_CR14","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/S0140-6736(23)01611-2","volume":"402","author":"M Kamdar","year":"2023","unstructured":"Kamdar M. Embracing chimeric antigen receptors for relapsed chronic lymphocytic leukaemia. Lancet. 2023;402:590\u20132.","journal-title":"Lancet"},{"key":"1020_CR15","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1056\/NEJMoa040258","volume":"351","author":"CHM Jamieson","year":"2004","unstructured":"Jamieson CHM, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl J Med. 2004;351:657\u201367.","journal-title":"N. Engl J Med"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01020-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01020-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01020-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T06:02:04Z","timestamp":1709704924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01020-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1020"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01020-y","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,6]]},"assertion":[{"value":"22 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}